Gastroenterologist perceptions of faecal microbiota transplantation

World Journal of Gastroenterology

Volumn 21, Issue 38, 2015, Pages 10907-10914

  Paramsothy, Sudarshan ^a   Walsh, Alissa J ^a   Borody, Thomas ^b   Samuel, Douglas ^c   Van Den Bogaerde, Johan ^d   Leong, Rupert W L ^c   Connor, Susan ^e   Ng, Watson ^e   Mitchell, Hazel M ^f   Kaakoush, Nadeem O ^f   Kamm, Michael A ^g  

^a ST VINCENT S HOSPITAL   (Australia)

^b Centre for Digestive Diseases   (Australia)

^c BANKSTOWN LIDCOMBE HOSPITAL   (Australia)

^d NAMBOUR GENERAL HOSPITAL   (Australia)

^e LIVERPOOL HOSPITAL   (Australia)

^f UNIVERSITY OF NEW SOUTH WALES   (Australia)

^g UNIVERSITY OF MELBOURNE   (Australia)

Author keywords

Clostridium difficile; Faecal microbiota transplantation; Gastroenterologist; Inflammatory bowel disease; Perceptions

Indexed keywords

ENEMA;

ARTICLE; AUSTRALIA; CLINICAL EFFECTIVENESS; CLINICAL TRIAL (TOPIC); CLOSTRIDIUM DIFFICILE INFECTION; CROHN DISEASE; DISEASE EXACERBATION; FECAL MICROBIOTA TRANSPLANTATION; FECES MICROFLORA; GASTROENTEROLOGIST; HUMAN; INFECTION RISK; IRRITABLE COLON; NASODUODENAL FECAL MICROBIOTA TRANSPLANTATION; ORAL FECAL MICROBIOTA TRANSPLANTATION; PHYSICIAN ATTITUDE; TRANSCOLONOSCOPIC FECAL MICROBIOTA TRANSPLANTATION; TRANSPLANTATION; TREATMENT INDICATION; ULCERATIVE COLITIS; ADVERSE EFFECTS; COLITIS, ULCERATIVE; ENTEROCOLITIS, PSEUDOMEMBRANOUS; GASTROENTEROLOGY; HEALTH CARE DELIVERY; HEALTH PERSONNEL ATTITUDE; IRRITABLE BOWEL SYNDROME; PEPTOCLOSTRIDIUM DIFFICILE; PERCEPTION; PROCEDURES;

ATTITUDE OF HEALTH PERSONNEL; AUSTRALIA; CLOSTRIDIUM DIFFICILE; COLITIS, ULCERATIVE; CROHN DISEASE; ENTEROCOLITIS, PSEUDOMEMBRANOUS; FECAL MICROBIOTA TRANSPLANTATION; GASTROENTEROLOGY; HEALTH SERVICES ACCESSIBILITY; HUMANS; IRRITABLE BOWEL SYNDROME; PERCEPTION;

EID: 84944096837     PISSN: 10079327     EISSN: 22192840     Source Type: Journal    
DOI: 10.3748/wjg.v21.i38.10907     Document Type: Article

References (22)

1. Smith MB, Kelly C, Alm EJ. Policy: How to regulate faecal transplants. Nature 2014; 506: 290-291 [PMID: 24558658 DOI: 10.1038/506290a]
2. Lessa FC, Mu Y, Bamberg WM, Beldavs ZG, Dumyati GK, Dunn JR, Farley MM, Holzbauer SM, Meek JI, Phipps EC, Wilson LE, Winston LG, Cohen JA, Limbago BM, Fridkin SK, Gerding DN, McDonald LC. Burden of Clostridium difficile infection in the United States. N Engl J Med 2015; 372: 825-834 [PMID: 25714160 DOI: 10.1056/NEJMoa1408913]
3. Leffler DA, Lamont JT. Clostridium difficile infection. N Engl J Med 2015; 372: 1539-1548 [PMID: 25875259 DOI: 10.1056/NEJMra1403772]
4. Gough E, Shaikh H, Manges AR. Systematic review of intestinal microbiota transplantation (fecal bacteriotherapy) for recurrent Clostridium diffcile infection. Clin Infect Dis 2011; 53: 994-1002 [PMID: 22002980 DOI: 10.1093/cid/cir632]
5. Kassam Z, Lee CH, Yuan Y, Hunt RH. Fecal microbiota transplantation for Clostridium difficile infection: systematic review and meta-analysis. Am J Gastroenterol 2013; 108: 500-508 [PMID: 23511459 DOI: 10.1038/ajg.2013.59]
6. van Nood E, Vrieze A, Nieuwdorp M, Fuentes S, Zoetendal EG, de Vo s WM, Visser CE, Kuijper EJ, Bartelsman JF, Tijssen JG, Speelman P, Dijkgraaf MG, Keller JJ. Duodenal infusion of donor feces for recurrent Clostridium diffcile. N Engl J Med 2013; 368: 407-415 [PMID: 23323867 DOI: 10.1056/NEJMoa1205037]
7. Turnbaugh PJ, Ley RE, Hamady M, Fraser-Liggett CM, Knight R, Gordon JI. The human microbiome project. Nature 2007; 449: 804-810 [PMID: 17943116 DOI: 10.1038/nature06244]
8. Peterson J, Garges S, Giovanni M, McInnes P, Wang L, Schloss JA, Bonazzi V, McEwen JE, Wetterstrand KA, Deal C, Baker CC, Di Francesco V, Howcroft TK, Karp RW, Lunsford RD, Wellington CR, Belachew T, Wright M, Giblin C, David H, Mills M, Salomon R, Mullins C, Akolkar B, Begg L, Davis C, Grandison L, Humble M, Khalsa J, Little AR, Peavy H, Pontzer C, Portnoy M, Sayre MH, Starke-Reed P, Zakhari S, Read J, Watson B, Guyer M. The NIH Human Microbiome Project. Genome Res 2009; 19: 2317-2323 [PMID: 19819907 DOI: 10.1101/gr.096651.109]
9. Neish AS. Microbes in gastrointestinal health and disease. Gastroenterology 2009; 136: 65-80 [PMID: 19026645 DOI: 10.1053/j.gastro.2008.10.080]
10. Gevers D, Kugathasan S, Denson LA, Vázquez-Baeza Y, Van Treuren W, Ren B, Schwager E, Knights D, Song SJ, Yassour M, Morgan XC, Kostic AD, Luo C, González A, McDonald D, Haberman Y, Walters T, Baker S, Rosh J, Stephens M, Heyman M, Markowitz J, Baldassano R, Griffths A, Sylvester F, Mack D, Kim S, Crandall W, Hyams J, Huttenhower C, Knight R, Xavier RJ. The treatment-naive microbiome in new-onset Crohn's disease. Cell Host Microbe 2014; 15: 382-392 [PMID: 24629344 DOI: 10.1016/j.chom.2014.02.005]
11. Manichanh C, Borruel N, Casellas F, Guarner F. The gut microbiota in IBD. Nat Rev Gastroenterol Hepatol 2012; 9: 599-608 [PMID: 22907164 DOI: 10.1038/nrgastro.2012.152]
12. Sears CL, Garrett WS. Microbes, microbiota, and colon cancer. Cell Host Microbe 2014; 15: 317-328 [PMID: 24629338 DOI: 10.1016/j.chom.2014.02.007]
13. Le Chatelier E, Nielsen T, Qin J, Prifti E, Hildebrand F, Falony G, Almeida M, Arumugam M, Batto JM, Kennedy S, Leonard P, Li J, Burgdorf K, Grarup N, Jørgensen T, Brandslund I, Nielsen HB, Juncker AS, Bertalan M, Levenez F, Pons N, Rasmussen S, Sunagawa S, Tap J, Tims S, Zoetendal EG, Brunak S, Clément K, Doré J, Kleerebezem M, Kristiansen K, Renault P, Sicheritz-Ponten T, de Vos WM, Zucker JD, Raes J, Hansen T, Bork P, Wang J, Ehrlich SD, Pedersen O. Richness of human gut microbiome correlates with metabolic markers. Nature 2013; 500: 541-546 [PMID: 23985870 DOI: 10.1038/nature12506]
14. Ridaura VK, Faith JJ, Rey FE, Cheng J, Duncan AE, Kau AL, Griffn NW, Lombard V, Henrissat B, Bain JR, Muehlbauer MJ, Ilkayeva O, Semenkovich CF, Funai K, Hayashi DK, Lyle BJ, Martini MC, Ursell LK, Clemente JC, Van Treuren W, Walters WA, Knight R, Newgard CB, Heath AC, Gordon JI. Gut microbiota from twins discordant for obesity modulate metabolism in mice. Science 2013; 341: 1241214 [PMID: 24009397 DOI: 10.1126/science.1241214]
15. Tang WH, Wang Z, Fan Y, Levison B, Hazen JE, Donahue LM, Wu Y, Hazen SL. Prognostic value of elevated levels of intestinal microbe-generated metabolite trimethylamine-N-oxide in patients with heart failure: refining the gut hypothesis. J Am Coll Cardiol 2014; 64: 1908-1914 [PMID: 25444145 DOI: 10.1016/j.jacc.2014.02.617]
16. Schnabl B, Brenner DA. Interactions between the intestinal microbiome and liver diseases. Gastroenterology 2014; 146: 1513-1524 [PMID: 24440671 DOI: 10.1053/j.gastro.2014.01.020]
17. Kahn SA, Vachon A, Rodriquez D, Goeppinger SR, Surma B, Marks J, Rubin DT. Patient perceptions of fecal microbiota transplantation for ulcerative colitis. Infamm Bowel Dis 2013; 19: 1506-1513 [PMID: 23624888 DOI: 10.1097/MIB.0b013e318281f520]
18. Alang N, Kelly CR. Weight gain after fecal microbiota transplantation. Open Forum Infect Dis 2015; 2: ofv004 [PMID: 26034755 DOI: 10.1093/ofd/ofv004]
19. Zipursky JS, Sidorsky TI, Freedman CA, Sidorsky MN, Kirkland KB. Patient attitudes toward the use of fecal microbiota transplantation in the treatment of recurrent Clostridium diffcile infection. Clin Infect Dis 2012; 55: 1652-1658 [PMID: 22990849 DOI: 10.1093/cid/cis809]
20. Brandt LJ. Editorial commentary: fecal microbiota transplantation: patient and physician attitudes. Clin Infect Dis 2012; 55: 1659-1660 [PMID: 22990845 DOI: 10.1093/cid/cis812]
21. Kelly C, de Leon L, Kerstetter D, Okpara N. Barriers to Greater Utilization of Fecal Bacteriotherapy for Chronic Clostridium diffcile Infection (abstract). American College of Gastroenterology annual meeting; San Antonio, Texas; 15-20 October, 2010
22. Sof AA, Georgescu C, Sodeman T, Nawras A. Physician outlook toward fecal microbiota transplantation in the treatment of Clostridium difficile infection. Am J Gastroenterol 2013; 108: 1661-1662 [PMID: 24091517 DOI: 10.1038/ajg.2013.207]